GlassScriptPhysician profile
Ramin Farboudmanesch
NPI 1669433215
$6,678.60
in general payments reported to CMS, 2019-2025
35 companies · $927 in 2025
The $927 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $990 · 2020: $732 · 2021: $1,395 · 2022: $1,269 · 2023: $923 · 2024: $442 · 2025: $927.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,293.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,292.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,134.34 | 2019-2023 | Xifaxan, Plenvu |
| Abbvie INC. | $963.63 | 2019-2025 | |
| Qol Medical, LLC | $624.44 | 2021-2025 | Sucraid, Sucraid |
| Celgene Corporation | $482.13 | 2021-2023 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $447.28 | 2022-2025 | Dupixent |
| Novo Nordisk INC | $338.68 | 2019-2025 | Wegovy |
| Allergan, INC. | $335.49 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $312.55 | 2019-2022 | |
| Apollo Endosurgery US INC | $266.14 | 2022-2023 | Overstitch Endoscopic Suturing System |
| Pfizer INC. | $263.27 | 2020-2025 | |
| Phathom Pharmaceuticals, INC. | $260.53 | 2024-2025 | Voquezna |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $162.52 | 2019-2021 | |
| Janssen Biotech, INC. | $160.72 | 2019-2025 | Tremfya, Stelara |
| Genzyme Corporation | $117.41 | 2022-2025 | |
| Nestle Healthcare Nutrition INC. | $100.87 | 2021-2023 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $90.30 | 2021 | |
| Intercept Pharmaceuticals, INC. | $75.63 | 2020-2022 | |
| Madrigal Pharmaceuticals | $70.72 | 2024-2025 | Resmetirom, Rezdiffra |
| Lilly USA, LLC | $54.19 | 2025 | Omvoh |
| Braintree Laboratories, INC. | $50.25 | 2021-2022 | |
| Gilead Sciences, INC. | $42.67 | 2019-2022 | |
| Aspire Bariatrics, INC. | $41.86 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $35.92 | 2023-2024 | Entyvio |
| Evoke Pharma, INC. | $33.70 | 2024 | |
| Exact Sciences Corporation | $29.09 | 2025 | Cologuard Collection Kit |
| Ambu INC. | $28.05 | 2022 | |
| Echosens North America, INC. | $26.94 | 2023 | Fibroscan |
| Boston Scientific Corporation | $20.58 | 2019 | |
| Alfasigma USA, INC. | $19.36 | 2020 | |
| Capsovision, INC. | $17.87 | 2023 | Capsocam Plus |
| Daiichi Sankyo INC. | $17.14 | 2019 | |
| Aimmune Therapeutics, INC. | $16.53 | 2025 | Zenpep |
| W. L. Gore & Associates, INC. | $13.91 | 2020 | |
| Lexicon Pharmaceuticals, INC. | $12.68 | 2019 | |
| Shire North American Group INC | $11.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramin Farboudmanesch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.